Modification of atherosclerosis by agents that do not lower cholesterol.
Cleland
J G
JG
Department of Medicine (Cardiology), Royal Postgraduate Medical School, Hammersmith Hospital, London.
Krikler
D M
DM
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011341:Probucol / Q000627:therapeutic use; D011817:Rabbits; D014815:Vitamins / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
D000975:Antioxidants; D002121:Calcium Channel Blockers; D005343:Fibrinolytic Agents; D014815:Vitamins; D014859:Warfarin; D006493:Heparin; D011341:Probucol; D001241:Aspirin